To establish the potential clinical relevance of MYCN regulation of the clock, we examined how the expression of the main clock component (BMAL1) and its activator (RORα) and repressor (REV-ERBα) related to clinical outcome and MYCN amplification in human NB primary tumors. This evidence concerns the gene MYCN and neuroblastoma.